{
    "root": "8df39b9c-af70-4ac3-ba9f-6e8e795ba961",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "CELECOXIB",
    "value": "20250312",
    "ingredients": [
        {
            "name": "CELECOXIB",
            "code": "JCX84Q7J1L"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        }
    ],
    "indications": "Celecoxib is a non-steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) ( 1.1 ) Rheumatoid Arthritis (RA) ( 1.2 ) Juvenile Rheumatoid Arthritis (JRA) in      patients 2 years and older ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Acute Pain (AP) ( 1.5 ) Primary Dysmenorrhea (PD) ( 1.6 )",
    "contraindications": "Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. ( 2.1 ) OA: 200 mg once daily or 100 mg twice daily. ( 2.2 , 14.1 ) RA: 100 mg to 200 mg twice daily. ( 2.3 , 14.2 ) JRA: 50 mg twice daily in patients 10 kg to 25 kg. 100 mg twice daily in patients more than 25 kg. ( 2.4 , 14.3 ) AS: 200 mg once daily single dose or 100 mg twice daily. If no effect is observed after 6 weeks, a trial of 400 mg (single or divided doses) may be of benefit. ( 2.5 , 14.4 ) AP and PD: 400 mg initially, followed by 200 mg dose if needed on first day. On subsequent days, 200 mg twice daily as needed. ( 2.6 , 14.5 ) Hepatic Impairment: Reduce daily dose by 50% in patients with moderate hepatic impairment (Child-Pugh Class B). ( 2.7 , 8.6 , 12.3 ) Poor Metabolizers of CYP2C9 Substrates: Consider a dose reduction by 50% (or alternative management for JRA) in patients who are known or suspected to be CYP2C9 poor metabolizers, ( 2.7 , 8.8 , 12.3 ).",
    "warningsAndPrecautions": "Celecoxib Capsules are available in the following strengths and configurations:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                               Product Name\n                              \n                           \n                           \n                               Description\n                              \n                           \n                           \n                               Size\n                              \n                           \n                           \n                               NDC number\n                              \n                           \n                        \n                        \n                            Celecoxib Capsules 50 mg\n                           \n                            White to off white colored granules filled in size 2 hard gelatin white capsule,  axially printed with 'Cipla' on cap & '423' over '50 mg' on body in red ink.\n                           \n                            Bottle of 30 capsules Bottle of 60 capsules\n                           \n                            69097-423-02 69097-423-03\n                           \n                        \n                        \n                            Celecoxib Capsules 100 mg\n                           \n                            White to off white colored granules filled in size 2 hard gelatin white capsule,  axially printed with 'Cipla' on cap & '422' over '100 mg' on body in blue ink.\n                           \n                            Bottle of 30 capsules Bottle of 100 capsules Bottle of 500 capsules 10's Blister Carton of 100 (10 x 10) Unit- dose Capsules\n                           \n                            69097-422-02 69097-422-07 69097-422-12 69097-422-19 69097-422-21\n                           \n                        \n                        \n                            Celecoxib Capsules 200 mg\n                           \n                            White to off white colored granules filled in size 1 hard gelatin white capsule,  axially printed with 'Cipla' on cap & '421' over '200 mg' on body in gold ink.\n                           \n                            Bottle of 30 capsules Bottle of 100 capsules Bottle of 500 capsules 10's Blister Carton of 100 (10 x 10) Unit- dose Capsules\n                           \n                            69097-421-02 69097-421-07 69097-421-12 69097-421-19 69097-421-21\n                           \n                        \n                        \n                            Celecoxib Capsules 400 mg\n                           \n                            White to off white colored granules filled in size 0el hard gelatin white capsule,  axially printed with 'Cipla' on cap & '420' over '400 mg' on body in green ink.\n                           \n                            Bottle of 30 capsules Bottle of 60 capsules Bottle of 480 capsules 10's Blister Carton of 100 (10 x 10) Unit- dose Capsules\n                           \n                            69097-420-02 69097-420-03 69097-420-11 69097-420-19 69097-420-21\n                           \n                        \n                     \n                  \n                  \n                     \n                        Storage:\n                      \n                  Store at 25°C (77°F) excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions": "Known hypersensitivity to celecoxib, or any components of the drug product or sulfonamides. ( 4 ) History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. ( 4 ) In the setting of CABG surgery. ( 4 )"
}